India: Pharmaceutical Products -What is not Patentable under Indian Law?

Last Updated: 17 October 2005
Article by Manisha Singh


The determination of patentability of a particular invention is perhaps the most daunting and consuming task in the entire process of grant of a patent. For an innovation to qualify the criteria of invention it must be new, involve an inventive step and should be capable of industrial application. However, the existence of these preliminary requirements would not alone entitle an invention to claim patent protection. The invention must also escape the exclusionary clauses under the Patents Act.

Section 3 of the Patents Act, 1970 excludes certain inventions from the ambit of patentability. Though there is an exhaustive list of fifteen exclusions from patentability mentioned in the Act, only three exclusions enumerated in clauses (d), (e) and (i) of section 3 are relevant from the perspective of pharmaceutical products in India. These clauses exclude new use of the known substance, mere admixture of components and methods of treatment respectively from the ambit of term ‘invention’ and hence render them unpatentable. All these exceptions have been provided in conformity of the categories for exclusions mentioned in the TRIPS Agreement.

This article is an attempt to analyze these exclusions from a global perspective and study their ramifications on the Indian pharmaceutical companies.

Swiss claims

It is a cardinal principle of patent law across all the national jurisdictions that for an invention to be patentable, it must be ‘new’, involve an ‘inventive step’ and should be capable of ‘industrial application’. Novelty is regarded as the most important criterion on which patentability hinges. Where a ‘new chemical entity, having therapeutic effect is discovered, it is per se entitled to patent protection. Where although the substance or chemical composition is known but its medical use is unknown, the ‘first medical use’ of such substance or chemical composition is also equally eligible for patent protection provided it fulfills the requisites for the same. The claim for the ‘first medical use’ is generally in the form ‘substance X for the use in the treatment of medical condition Y’.

There are many substances or chemical compositions that have more than one therapeutic effect or medical use. Where subsequent research brings forth the ‘second medical use’ that was not anticipated, such ‘second medical use’ of the substance already known to have a medical use is also protected in several national jurisdictions. Such types of claims are known as ‘Swiss claims’. Swiss claims can be defined as ‘the claim for the use of a substance or composition that has already been used for medical purpose for a ‘specified new medical purpose’. Swiss type of the claim may be illustrated as follows:

"The use of (substance X) in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of (medical condition Y)."

Swiss type claims mark a digression from the absolute rule of ‘novelty’ in as much as here the substance or the composition in the claim already forms part of the ‘prior art’. The concept of novelty is not abandoned in toto but is modified to mean the novelty of ‘intended use’. Novelty here means discovery of the ‘previously unrecognized advantageous property’ of a chemical compound. Like claims for patent protection of new product, the ‘first medical use’ and Swiss type claims must also meet the criteria of patentability viz. they must be new, involve an inventive step and should be capable of industrial application.

Even though the conventional notion of novelty is not satisfied, Swiss Claims are protected as a matter of policy inasmuch as considerable efforts go into finding out new therapeutic use of known substances. Swiss claims are protected only if the national laws recognize them. There is no international obligation to give effect to such claims and therefore many national laws have excluded Swiss claims from patentability.

Indian Law

The Patents Act, 1970 as originally enacted did not recognize patent protection for the any substance intended to be used or capable of being used as a medicine or drug. In other words, even the first medical use of any chemical substance was not patentable. Therefore, the question of patent protection for the second medical use or the Swiss Claims was explicitly ruled out. Section 3(d) provided that mere discovery of any new property or new use for a known substance is not an invention. Further the process for the medicinal, surgical, curative, prophylactic or other treatment of the human beings was also kept outside the purview of term invention.

The Patents (Amendment) Ordinance, 2004 amended Section 3 (d) and substituted the words ‘new use’ with the words ‘mere new use’ of the known substance. The term ‘mere new use’ was thought to give way to Swiss claims in India as where the new use leads to a medically or therapeutically useful effect it may be patentable. The Patents (Amendment) Act, 2005 substituted the above section with a new one. It reverted to ‘new use’ from ‘mere new use’ of the known substance. Under the current law salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of the known substances are to be considered the same unless they differ significantly in properties with regard to efficacy.

However, under Section 3(d) any invention that enhances the known efficacy of the substance or results in a new product or employs at least one new reactant is patentable and that only the mere discovery of a new form or of any new property or new form of any new property or new use of a known substance or process is excluded.

The amended section makes it amply clear that Swiss type claims shall not be accepted for patent protection in India. Just about any improvement made to the known substance shall not merit protection. Salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of the known substances shall be taken to be part of the ‘prior art’ unless they exhibit a higher degree of inventive step.

Admixture of known components

According to section 3(e), a substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof or a process of producing such substance is not an invention within the meaning of the Patent Act.

Thus section 3(e) of the Indian Patents Act denies claims to pharmaceutical composition with a single active ingredient, even if the active compound is novel, as it bars compositions obtained by mere admixture resulting only in the aggregation of the properties of the components thereof. In other words a novel pharmaceutical composition with a single active ingredient (known or novel) with an inert carrier is not patentable in India as there is no synergy between the components viz. the active compound and the inert carrier.

Methods of Treatment

The rationale for excluding methods of treatment from patentability is that methods of treatment are not capable of industrial application. Another reason is the policy that the medical men who use methods as a part of their duties should not be inhibited by the existence of patent protection. The methods of treatment require medical skill of a medical practitioner and not merely intake of medicines by the patient and therefore the methods of treatment are not capable of manufacture unlike the pharmaceutical products or in other words are not capable of industrial application and hence cannot be patented.

In Bristol-Myers Squibb v Baker Norton Pharmaceuticals Inc, (1999), considered the purpose of exclusion of methods of treatments. Jacob J. observed:

"Its purpose is merely to keep patent law from interfering directly with what a doctor actually does to a patient, not to stop patent monopolies from controlling what the doctor administers to the patient or the implements that he uses on the patient".

Indian Law

Indian patent law expressly excludes methods of treatment of human beings and animals from patentability. Section 3(i) of the Patents Act 1970 as amended declares that the term invention does not encompass ‘any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for the similar treatment of animals to render them free of disease or to increase their economic value or that of their products’.

Under the original act of 1970 only process for medicinal, surgical, curative, prophylactic or other treatment were excluded from patent protection. Diagnostic and therapeutic treatment was included in this category by the Patent (Second Amendment) Act of 2002.

The Act does not define the meaning of the terms ‘medicinal’, ‘surgical’, ‘curative’, ‘prophylactic’, ‘diagnostic’, ‘therapeutic’ treatments. It is important to define the contours of these terms as those methods that do not fall in any of the specified categories would not be excluded from patentability.

In order to determine the exact scope of the exclusion it is necessary to understand the meaning of the terms-‘surgical’, ‘therapeutic’ and ‘diagnostic’ treatment. The term ‘therapy’ may be defined as ‘any treatment which is designed to cure, alleviate, remove or lessen the symptoms of, or to prevent or reduce the possibility of contracting any disorder or malfunction of the human or animal body. Therapeutic treatment may be defined as a course of treatment undertaken with the ‘intention to improve the health of the human or animal being treated’.

Surgery has been defined as ‘the field of medicines involving the healing of diseases or accident injuries, or remedies against physical defects by means of surgical intervention performed in a body’. Diagnostic methods generally include those methods "… in which the examination, i.e., both the determination of the present state of health and the symptoms of illness is carried out directly on body".

The Patent Act is silent on the point as to whether the new substances or compositions and apparatus used in such methods of treatment would be patentable or not. Drawing analogy from the law on the point in other jurisdictions such as EU, U.K. it may be assumed that though the process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment has been excluded, the products that are used in such treatment are patentable. Similarly the instruments and apparatus that are used in such treatment should also be patentable.

There are no judicial precedents in India on the patentability of methods of treatment so as to guide the interpretation of this exclusionary clause. The law on the ‘method of treatment’ has been extensively analyzed, explored and interpreted by the European Patent Office (EPO) and the national laws of the EU members. Elaborate guidelines are formulated by the EPO to aid the examination of the claims relating to the patent of ‘methods of treatment’. In order to understand the nuances of the nature and extent of exclusion, we have to study the legal provisions and the corresponding interpretations of the ‘methods of treatment’ in the other jurisdictions.


From the perspective of the pharmaceutical industry exclusion of Swiss-type claims may not be a welcome step. Whereas their counterparts in developed countries enjoy the extended patented protection by developing their basic invention, they may not avail this benefit. Pharmaceutical research in India will not be inclined towards the further improvement of the already known chemical substance. This would also prevent discovery of new therapeutic uses of the known substances.

Instead of placing Swiss claims outside the purview of patent protection, it would have been better if such claims were allowed in limited circumstances. To thwart bogus claims, Indian Patent Office should have evolved elaborate guidelines for the acceptance of Swiss Claims. This measure would have galvanized research in the area of discovering new therapeutic uses on the known substances in India.

Under the U.K and Australian law, purely cosmetic treatment of human and animals are patentable. Where a method of treatment involves both the therapeutic and cosmetic effects, the cosmetic effect would be patentable if it is distinct from the therapeutic effects. Whereas the exclusionary clause under the European law is exhaustive and excludes only therapeutic, diagnostic and surgerical methods of treatment, the Indian provisions is inclusive in nature and includes ‘other treatment’ also. It is not certain if purely cosmetic methods of treatment are patentable in India.

Many issues that have already confronted the courts of other countries regarding the scope and extent of exclusion of ‘methods of treatment’ shall confront Indian courts soon. Patenting of methods of treatments should not be given liberal construction in India. The medical costs are bound to escalate after the introduction of the product patent regime for pharmaceuticals; it should not be allowed to increase by patenting the methods of treatment.

© Lex Orbis 2005

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions